Filing Flows › Anika Therapeutics (ANIK) › Q3 2026
Anika Therapeutics (ANIK) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
Anika Therapeutics (ANIK) reported revenue of $30.6M for the third quarter 2026 (Q3 2026), +10% from a year earlier and -6% from the quarter before. Operating margin was -2.3%, net loss $311K (1.0% of revenue).
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.6M | -6% | +10% |
| Operating profit | −$712K | -124% | — |
| Net earnings | −$311K | -109% | — |
| Operating cash flow | $8.4M | — | +22% |
| Free cash flow | $6.7M | — | +35% |
What changed
Revenue was $30.6M in Q3 2026, up 10% year over year and down 6% from the previous quarter. OEM Channel was the largest line at 54% of revenue. Commercial Channel added $2.0M year over year (up 17%), 73% of the total change.
Gross margin was 61.6%, up 5.5 points from Q3 2025. Operating costs exceeded revenue by $712K, an operating margin of -2.3%. Operating expenses grew 4% against revenue growth of 10%. The fastest-growing cost line was Research & development (+14%). The quarter ended with a net loss of $311K, after a profit of $3.3M the previous quarter. Non-operating items added $390K, -121% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $8.4M (up 22% year over year). Non-cash charges added back $1.4M of depreciation and amortization and $4.2M of share-based compensation. Working capital and other items added $3.0M. Capital expenditures of $1.7M left free cash flow of $6.7M.
Questions
What was Anika Therapeutics' revenue in the third quarter 2026?
Anika Therapeutics (ANIK) reported revenue of $30.6M for the third quarter 2026 (Q3 2026), +10% from a year earlier and -6% from the quarter before.
Was Anika Therapeutics profitable in the third quarter 2026?
Operating loss was $712K (-2.3% of revenue) and net loss $311K.
Source: Anika Therapeutics 10-Q on SEC EDGAR.